Intermittent Fasting on GLP-1 Medications: Safety and Nutritional Considerations
Intermittent fasting (IF), which involves restricting eating to specific windows or periods of very limited food intake, may not be universally safe or beneficial for individuals taking Glucagon-like peptide-1 (GLP-1) medicines or tirzepatide. These medications already reduce hunger and can cause digestive symptoms, making the addition of a restrictive eating pattern potentially problematic. There is no established single fasting schedule proven safe or beneficial for all users of these medicines. Patients with diabetes, kidney disease, frailty, a history of eating disorders, or those experiencing repeated dizziness or difficulty meeting nutritional needs should seek individual medical advice before attempting any fasting regimen. Furthermore, pregnant or breastfeeding individuals and growing children should not engage in self-directed weight-loss fasting. Starting or increasing the dose of GLP-1 medicines can induce nausea or vomiting, and fasting should be avoided until intake stabilizes. During illness ...
